1. Warnakulasuriya S, Greenspan JS (2020) Epidemiology of Oral and Oropharyngeal Cancers. In Textbook of Oral Cancer, 1st ed; Springer International Publishing 5-21.
2. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (2017) WHO classification of Head and Neck Tumours, 4th ed.; International Agency for Research on Cancer 9: 109.
3. Rothenberg SM, Ellisen LW (2012) The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest, 122: 1951-7.
4. The Surveillance E, and End Results (SEER) Cancer Stat Facts: Oral Cavity and Pharynx Cancer.
5. Moro JDS, Maroneze MC, Ardenghi TM, Barin LM, Danesi CC (2018) Oral and oropharyngeal cancer: epidemiology and survival analysis. Einstein 16: eAO4248.
6. Le Campion A (2017) Low Survival Rates of Oral and Oropharyngeal Squamous Cell Carcinoma. Int J Dent 5815493.
7. Gharat SA, Momin M, Bhavsar C (2016) Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Crit Rev Ther Drug Carrier Syst 33: 363-400.
8. Wong SJ, Heron DE, Stenson K, Ling DC, Vargo JA (2016) Locoregional Recurrent or Second Primary Head and Neck Cancer: Management Strategies and Challenges. Am Soc Clin Oncol Educ Book 35: 284-92.
9. Oksuz DC (2011) Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. Radiat Oncol 6.
10. Epstein JB, Gorsky M, Cabay RJ, Day T, Gonsalves W (2008) Screening for and diagnosis of oral premalignant lesions and oropharyngeal squamous cell carcinoma: role of primary care physicians. Can Fam Physician 54: 870-5.
11. Warnakulasuriya S (2010) Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 46: 407-10.
12. Martínez C, Hernández M, Martínez B, Adorno D (2016) Frequency of oral squamous cell carcinoma and oral epithelial dysplasia in oral and oropharyngeal mucosa in Chile. Rev Med Chil, 144: 169-74.
13. Zimmer K (2019) Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. Comput Struct Biotechnol J 17: 447-53.
14. Wheler JJ (2016) TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther 15: 2475-85.
15. Kato S (2019) Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol 3: 18.00180.
16. Hou H (2019) Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res 11: 5665-75.
17. Rapidis A, Sarlis N, Lefebvre JL, Kies M (2008) Docetaxel in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag 4: 865-86.
18. Vermorken JB (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-27.
19. Meldrum C, Doyle MA, Tothill RW (2011) Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 32: 177-95.
20. Wilson BJ, Miller FA, Rousseau F (2017) Controversy and debate on clinical genomics sequencing-paper 1: genomics is not exceptional: rigorous evaluations are necessary for clinical applications of genomic sequencing. J Clin Epidemiol 92: 10.1016/j.jclinepi.2017.08.018.
21. Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-72.
22. Szabó B (2011) Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 47: 487-96.
23. Temam S (2007) Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-70.
24. Chung CH (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-6.
25. Zhang W, Liu H (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18.
26. Bryan BA (2010) RhoA/ROCK signaling is essential for multiple aspects of VEGF‐mediated angiogenesis. FASEB J 24: 3186-95.
27. Karar J, Maity A (2011) PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4: 51.
28. Weddell JC, Chen S, Imoukhuede PI (2017) VEGFR1 promotes cell migration and proliferation through PLCγ and PI3K pathways. NPJ Syst Biol Appl 4: 1.
29. Chuerduangphui J (2017) Amplification of EGFR and cyclin D1 genes associated with human papillomavirus infection in oral squamous cell carcinoma. Med Oncol 34: 148.
30. Huang SF (2012) Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncol 48: 67-72.
31. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 Mutations in Human Cancers. Science 253: 49-53.
32. National Institute of Health (2020) U.S. NIH National Library of Medicine, USA.
33. Leemans CR, Braakhuis BJ, Brakenhoff RH (2010) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
34. The Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576-82.
35. Hsu H (2019) TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer. Cancers 11: 1079.
36. Lindemann A, Takahashi H, Patel AA, Osman AA, Myers JN (2018) Targeting the DNA Damage Response in OSCC with TP53 Mutations. J Dent Res 97: 635-44.
37. Martín-Ezquerra G (2010) Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. Br J Dermatol 163: 1028-35.
38. Natan E (2011) Interaction of the p53 DNA-Binding Domain with Its N-Terminal Extension Modulates the Stability of the p53 Tetramer. J Mol Biol 409: 358-68.
39. Brand TM, Iida M, Wheeler DL (2011) Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11: 777-92.
40. Harris AL, Generali D (2014) Inhibitors of Tumor Angiogenesis. In Cancer Drug Design and Discovery (2nd Edn) Editor Neidle, S.; Elsevier, USA.
41. Fogli S (2018) Clinical pharmacology of intravitreal anti-VEGF drugs. Eye 32: 1010-20.
42. Zuazo-Gaztelu I, Casanovas O (2018) Unraveling the Role of Angiogenesis in Cancer Ecosystems. Front Oncol 8: 248.
43. Fu S (2015) Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol 26: 1012-8.
44. Koehler K, Liebner D, Chen JL (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27: 539-43.
45. Kato I (2013) Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. Mol Cell Biol 33: 340-59.
46. Cardinali M, Kratochvil FJ, Ensley JF, Robbins KC, Yeudall WA (1997) Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck. Mol Carcinog 18: 78-88.
47. Adkins D (2018) Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncol 19: 1082-93.
48. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
49. Claesson-Welsh L, Welsh M (2013) VEGFA and tumour angiogenesis. J Intern Med 273: 114-27.
50. Singh AD, Parmar S (2015) Ramucirumab (Cyramza): A Breakthrough Treatment for Gastric Cancer. P T 40: 430-68.
51. Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA (2013) Ramucirumab: a novel antiangiogenic agent. Future Oncol 9: 789-95.
52. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumour growth and angiogenesis. J Clin Oncol 23: 1011-27.
53. Ikuta K (2009) E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 15: 7229-37.
54. Capozzi M (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11: 3847-60.
55. Matsuki M (2018) Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med 7: 2641-53.
56. Qin BD (2019) Basket Trials for Intractable Cancer. Front Oncol 9: 229.
57. Strzebonska K, Waligora M (2019) Umbrella and basket trials in Oncology: ethical challenges. BMC Med Ethics 20: 58.